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Abstract
Background: DOTS as a strategy was introduced to the tuberculosis control programme in
Southern region of Ethiopia in 1996. The impact of the programme on treatment outcomes and
the trend in the service coverage for tuberculosis has not been assessed ever since. The aim of the
study was to assess trends in the expansion of DOTS and treatment outcomes for tuberculosis in
Hadiya zone in Southern Ethiopia.
Methods: 19,971 tuberculosis patients registered for treatment in 41 treatment centres in Hadiya
zone between 1994 and 2001 were included in the study. The data were collected from the unit
tuberculosis registers. For each patient, we recorded information on demographic characteristics,
treatment centre, year of treatment, disease category, treatment given, follow-up and treatment
outcomes. We also checked the year when DOTS was introduced to the treatment centre.
Results: Population coverage by DOTS reached 75% in 2001, and the proportion of patients
treated with short course chemotherapy increased from 7% in 1994 to 97% in 2001. Treatment
success for smear-positive tuberculosis rose from 38% to 73% in 2000, default rate declined from
38% to 18%, and treatment failure declined from 5% to 1%. Being female patient, age 15–24 years,
smear positive pulmonary tuberculosis, treatment with short course chemotherapy, and treatment
at peripheral centres were associated with higher treatment success and lower defaulter rates.
Conclusion: The introduction and expansion of DOTS in Hadiya has led to a significant increase
in treatment success and decrease in default and failure rates. The smaller institutions exhibited
better treatment outcomes compared to the larger ones including the zonal hospital. We identified
many patients with missing information in the unit registers and this issue needs to be addressed.
Further studies are recommended to see the impact of the programme on the prevalence and
incidence of tuberculosis.
Background
Ethiopia stands among the world's top 22 tuberculosis
(TB) high-burden countries, with an estimated annual
incidence of 250 TB cases/105 population [1,2]. In the
Southern Ethiopia Regional State (SNNPRS), TB is among
the leading causes for sickness and death [3]. As in many
other resource-constrained settings, treatment outcomes
for tuberculosis have not been satisfactory [4], mainly due
Published: 06 June 2005
BMC Public Health 2005, 5:62 doi:10.1186/1471-2458-5-62
Received: 12 January 2005
Accepted: 06 June 2005
This article is available from: http://www.biomedcentral.com/1471-2458/5/62
© 2005 Shargie and Lindtjørn; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Public Health 2005, 5:62 http://www.biomedcentral.com/1471-2458/5/62
Page 2 of 11
(page number not for citation purposes)
to poor treatment compliance and low coverage of short
course chemotherapy (SCC). Delays in the diagnosis and
treatment initiation, the devastating HIV/AIDS epidemic
and the potential threat of anti-tuberculosis drug resist-
ance represent serious threats to the TB control effort in
the region. The HIV co-infection among TB patients in the
region is estimated at 19% [5].
Directly Observed Treatment, Short-course (DOTS) was
introduced in the region in 1996. However, the impact of
DOTS and its effectiveness in the regional context has not
been assessed yet. Global reviews [6] and reports from
Asian, African and East European countries [7-9] have
favourable implications for the DOTS strategy. On the
contrary, some randomised controlled studies have failed
to establish the superiority of the most notable compo-
nent of this strategy, direct observation of treatment, over
the conventional non-observed treatment in improving
treatment outcomes [10,11]. Nevertheless, DOTS is
widely accepted and practised, with some TB high-burden
countries achieving almost full coverage of their popula-
tions [2]. DOTS is equally effective in curing TB patients
with HIV co-infection [9,12] and hence, its importance in
the era of the HIV/AIDS epidemic.
With this study, we aimed to assess the results and trends
in the expansion of DOTS in Hadiya Zone, Southern
Ethiopia.
Methods
Study setting
We did the study in Hadiya zone, Southern Ethiopia (see
map in Figure 1), with a population of 1.2 million
[13,14]. In addition to fifteen diagnostic centres, five
health centres and 21 health stations provide treatment
for TB patients referred or transferred from the diagnostic
centres, thus making the number of treatment centres 41.
All treatment units have standard Unit Registers from the
National Tuberculosis and Leprosy Control Programme
(TLCP). TB drugs used in a combination of two or more
in the region included isoniazid (H), rifampicin (R),
pyrazinamide (Z), ethambutol (E), streptomycin (S) and
thioacetazone (T).
The TB and Leprosy control programs were run as two sep-
arate vertical programs funded and managed mainly by
the All African Leprosy and Rehabilitation Training Centre
(ALERT) until the end of 1996 when the National and
Regional TLCP took over the responsibility. The zonal
TLCP gets administrative and technical support from the
regional TLCP, and monitors the activities in the diagnos-
tic and treatment centres through its seven woreda (dis-
trict) offices. The woreda health offices have standard
district TB registers from the National TLCP, and are
responsible for the distribution of drugs and reagents,
supervision of day to day activities in the treatment units,
collection of slides for quality control and record keeping.
Quarterly reports on cases detected and treatment out-
comes from the woredas are gathered at the zonal level
and sent to the regional TLCP.
In 1994, only Hossana Hospital provided unobserved
SCC for critically sick smear-positive pulmonary TB
(PTB+), miliary TB and tuberculosis meningitis cases.
DOTS was initiated in 1996 in two health facilities and
gradually expanded, first to the health centres in all wore-
das and then to the health stations. Details of treatment
regimens for various categories of patients under DOTS
are given in the NTLCP manual [15]. In brief, all new
patients were treated with SCC (two months on RHZ +/-
E or S, followed by 6 months on EH or RH), and were
required to take their medications under direct supervi-
sion by the health workers at least during the intensive
phase of treatment. During this phase, only critically ill
patients were hospitalised, while the rest received treat-
ment on ambulatory basis. Re-treatment cases were
treated with SERHZ for 2 months, ERHZ for 1 month and
ERH for 5 months. In non-DOTS areas treatment with
SCC was limited to critically sick PTB+, TB meningitis and
miliary TB cases while others received LCC (two months
on EH +/-S, followed by 10 months on EH; TH had also
been used as an alternative to EH until its recent
withdrawal).
Design and data collection
This is a retrospective trend analysis. The Unit Registers
reviewed contain basic information such as patient's age,
sex, address, category, TB type, drug regimen, date treat-
ment started, treatment follow-up, follow-up sputum
result and treatment outcomes.
We visited all 41 TB treatment centres during July-Novem-
ber 2002. We checked when DOTS was initiated in each
health institution and looked for the availability of TB
drugs and reagents during the time of visit. We then
reviewed the Unit Registers and entered the data to the
computer. At three peripheral treatment centres where the
unit registers could not be found, the respective district TB
registers were reviewed. For each TB case, we copied the
data from the registers to a computer program, SPSS for
windows [16], according to the standard definitions of the
National TLCP [15] on disease classification, patient cate-
gories, treatment regimens and treatment outcomes. To
ensure the quality of data entered into the computer data-
base, two people independently cross-checked each entry.
Data analysis and Statistics
The data were analysed using SPSS for Windows version
11.0 [16]. For categorical data, we used proportions with
95% confidence intervals, Odds ratio and Chi-square testBMC Public Health 2005, 5:62 http://www.biomedcentral.com/1471-2458/5/62
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to compare different groups. Multivariate analysis using
logistic regression model was used to analyse the associa-
tion between treatment outcomes and potential predictor
variables. We set the level of statistical significance at 5%.
Treatment outcomes were analysed for the years 1994–
2000 because a considerable proportion of patients regis-
tered during 2001 were still on treatment during the time
of data collection. (The Ethiopian fiscal year goes from
July to June. Fiscal year 2001, for example, goes from July
2001 through June 2002, and our study was commenced
in July 2002). Patients with unrecorded treatment out-
come were analysed as defaulters.
Results
Patient registration and case notification
A total of 19971 tuberculosis patients, 11138 (55.8%)
males and 8819 (44.2%) females were registered between
1994 and 2001 with the mean (SD) age of 25.6 (13.2)
years. Forty-six percent (n = 9232) of the patients were
PTB+ cases. Overall, 18687 (93.6%) patients were regis-
tered as new cases, 558 (2.8%) as transferred in, 273
(1.4%) as return after default, 142 (0.7%) as failure and
139 (0.7%) as relapse cases whereas patient category was
not recorded for 172 (0.9%) cases. Table 1 shows the gen-
eral characteristics of the patients.
The proportion of women among TB patients registered
for treatment remained at the range of 40–45% across the
years and at the range of 43–47% across the age groups
below 45. However, among patients older than 45 years,
the proportion of women was significantly lower (31%;
95%CI 29–33) compared to those below 45 (46%;
95%CI 45–47).
Table 1: General Characteristics of the study subjects (n = 
19971), 1994–2001
Characteristics Number Percent
Age group (years)
0–14 3356 16.8
15–24 6262 31.4
25–34 5366 26.9
35–44 2706 13.5
45–54 1248 6.2
55–64 501 2.5
≥  65 220 1.1
Unknown 312 1.6
Sex
Male 11138 55.8
Female 8819 44.2
Not mentioned 14 0.1
Patient Category
New 18687 93.6
Transferred-in 558 2.8
Return after default 273 1.4
Failure 142 0.7
Relapse 139 0.6
Unknown 172 0.9
TB Classification
Pulmonary positive 9232 46.2
Pulmonary negative 4225 21.2
Extra-pulmonary 6453 32.3
Unknown 61 0.3
Treatment Centre
Hossana Hospital 5362 26.8
Lemmo district health facilities 4011 20.1
Shashogo district health facilities 1208 6.0
Misha district health facilities 2660 13.3
Gibe district health facilities 1984 9.9
Soro district health facilities 2313 11.6
Duna district health facilities 216 1.1
Badewacho district health facilities 2217 11.1
Table 2: Trends in case notification of smear-positive pulmonary TB, Hadiya Zone, 1994–2001
Year Zonal Population* New PTB+ cases Reported 
(n = 8558)
Case Notification/ 105 
persons/year
Proportion of estimated 
PTB+ incident cases 
notified, %**
1994 1004000 512 49 45.2
1995 1070160 1025 96 87.9
1996 1101195 1162 106 96.8
1997 1133129 946 84 76.6
1998 1165990 1277 110 100.5
1999 1199804 1510 126 115.5
2000 1234598 1267 103 94.2
2001§ 1174118 858 73 67.0
*Projected from the 1994 Population and Housing Census, CSA [13]
**Estimated Incidence of PTB+ = 109/105 persons/year based on the WHO estimates of the Global Burden of Tuberculosis for 1997 [1]
§ Population adjusted as an area with about 70–80 thousand population was taken away from Hadiya to the neighbouring Silti zone between years 
2000 and 2001
PTB+: smear-positive pulmonary tuberculosisBMC Public Health 2005, 5:62 http://www.biomedcentral.com/1471-2458/5/62
Page 4 of 11
(page number not for citation purposes)
Among new cases, 46% (n = 8557) were PTB+ patients.
Except for the years 1997 (38%; 95%CI 36–40) and 2000
(56%; 95%CI 54–58), this proportion showed little vari-
ations in the range of 40–50%. Table 2 shows a trend in
the case notification of PTB+ over the study period. The
proportion of expected PTB+ incident cases notified
increased from 45% in 1994 to 116% in 1999, and
declined to 67% in 2001.
Table 3: Trend in treatment regimens for the different categories of patients (n = 19970).*
Category 1994 n (%) 1995 n (%) 1996 n (%) 1997 n (%) 1998 n (%) 1999 n (%) 2000 n (%) 2001 n (%)
All TB cases 1106 2201 2895 2742 3388 3253 2435 1950
SCC 73 (7) 311 (14) 288(10) 471 (17) 927 (27) 1881 (58) 2085 (86) 1883 (97)
LCC 1011 (91) 1684 (77) 2360 (82) 2097 (77) 2292 (68) 1302 (40) 304 (12) 20 (1)
No record 22 (2) 206 (9) 247 (8) 174 (6) 169 (5) 70 (2) 46 (2) 47 (2)
New PTB+ 512 1025 1162 946 1277 1510 1267 858
SCC 9 (2) 111 (11) 94 (8) 232 (24) 537 (42) 1170 (78) 1187 (94) 837 (97)
LCC 496 (97) 780 (76) 938 (81) 611 (65) 660 (52) 321 (21) 68 (5) 7 (1)
No record 7 (1) 134 (13) 130 (11) 103 (11) 80 (6) 19(1) 12 (1) 14 (2)
New PTB- 258 385 402 382 807 772 487 393
SCC 12 (5) 66 (17) 90 (22) 109 (28) 225 (28) 395 (51) 402 (83) 379 (96)
LCC 242 (94) 286 (74) 248 (62) 251 (66) 543 (67) 362 (47) 73 (15) -
No record 4 (1) 33 (9) 64 (16) 22 (6) 39 (5) 15 (2) 12 (2) 14 (4)
New EPTB 257 668 1177 1176 1124 721 528 570
SCC 19 (8) 73 (11) 57 (5) 70 (6) 97 (9) 197 (27) 385 (73) 559 (98)
LCC 232 (90) 565 (85) 1081 (92) 1067 (91) 993 (88) 513 (71) 138 (26) 6 (1)
No record 6 (2) 30 (4) 39 (3) 39 (3) 34 (3) 11 (2) 5 (1) 5 (1)
Relapse 81 32 12 91 51 91 91 5
SCC 2 (25) 10 (77) 12 (57) 21 (72) 13 (87) 17 (90) 19 (100) 14 (93)
LCC 4 (50) 2 (15) 9 (43) 6 (21) 2 (13) 2 (10) - -
N o  r e c o r d 2  ( 2 ) 1  ( 8 )- 2  ( 7 )--- 1  ( 7 )
After default 35 56 27 45 33 25 21 31
SCC 5 (14) 14 (25) 15 (56) 20 (45) 15 (46) 21 (84) 17 (81) 30 (97)
LCC 30 (86) 39 (70) 11(41) 23 (51) 18 (54) 4 (16) 4 (19) -
N o  r e c o r d - 3  ( 5 ) 1  ( 3 ) 2  ( 4 )--- 1  ( 3 )
After failure 28 38 17 17 13 19 8 2
SCC 26 (93) 35 (92) 15 (88) 13 (77) 11 (85) 14 (74) 8 (100) 2 (100)
LCC 2 (7) 3 (8) 2 (12) 4 (23) 2 (15) 5 (26) - -
N o  r e c o r d --------
Transferred in 6 3 65 131 89 120 86 57
SCC - - 3 (5) 3 (2) 22 (25) 43 (36) 53 (62) 38 (67)
LCC 5 (83) 2 (67) 55 (84) 124 (95) 58 (65) 57 (47) 19 (22) 7 (12)
No record 1 (17) 1 (33) 7 (11) 4 (3) 9 (10) 20 (17) 14 (16) 12 (21)
Missing info 21 31 71 02 04 61 32 9
SCC - 2 (15) 1 (5) 3 (30) 3 (15) 11 (24) 9 (69) 29 (100)
LCC - 7 (54) 12 (71) 6 (60) 11 (55) 30 (65) 2 (16) -
No record 2 4 (31) 4 (24) 1 (10) 6 (30) 5 (11) 2 (15) -
* Percentages are out of the total cases registered in the same category during the year.
PTB+ = smear-positive pulmonary tuberculosis; PTB- = smear-negative pulmonary tuberculosis; EPTB = extra-pulmonary tuberculosis
SCC = short course chemotherapy (2 months on RHZ+/- E or S, followed by 6 months on EH or RH)
LCC = long course chemotherapy (2 months on EH +/- S, followed by 10 months on EH; TH had also been used as an alternative to EH until its 
recent withdrawal).
R = Rifampicin,; H = Isoniazid; Z = Pyrazinamide; E = Ethambutol; S = Streptomycin; T = Thioacetazone.BMC Public Health 2005, 5:62 http://www.biomedcentral.com/1471-2458/5/62
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Treatment given
Forty percent (n = 7919) of patients received SCC. Treat-
ment regimen was not recorded for 981 (5%) cases. Table
3 presents trend in treatment regimens across the years by
TB classification. The proportion of patients treated with
SCC increased from 7% in 1994 to 58% in 1999, and 97%
in 2001 (χ 2
trend, p < 0.001).
During 1994–1997, more PTB- patents received SCC com-
pared to PTB+ patients (19% vs. 12%; p < 0.05) and EPTB
patients (19% vs. 7%; p < 0.05) among new cases of TB
(Table 3). This trend was reversed after 1997 when more
PTB+ patients (76%) were put on SCC, followed by PTB-
(57%) and EPTB (42%). There was no significant differ-
ence in the treatment regimens across the age groups and
between the two sexes.
Follow-up
Of the 8557 new PTB+ cases, sputum examination was
repeated at the end of two months treatment for 60% (n
= 5112), and 7.8% (n = 401) remained positive for AFB.
At the end of five months treatment, 2747 (32%) patients
had their sputum examined for AFB, and 78 (2.8%)
remained smear-positive. 1823 (21%) patients had their
sputum examined for AFB at (a month prior to) treatment
completion, and 1.4% (n = 26) remained smear-positive.
There has been a continuous and significant decline over
time in the sputum positivity at two months irrespective
of treatment regimen (Table 4).
Sputum positivity at the completion of fifth month treat-
ment remained at the range of 0–2% for those on SCC,
with the exception of 1995 and 1996 that exhibited 8%
and 5% respectively. For those on LCC, smear positivity at
5th month decreased from 12% in 1994 to 1% in 1999.
Overall, patients on LCC contributed more to the 5th
Table 4: Trends in the follow-up smear results for new smear positive pulmonary tuberculosis
2nd month 5th month End of treatment
Examined for AFB (% total) sm+ Examined for AFB (% total) Sm+ Examined for AFB (% total) sm+
Cases on SCC
1994 6 (67) 0 5 (56) 0 3 (33) 0
1995 79 (71) 18 (23%) 53 (48) 4 (8%) 33 (30) 0
1996 68 (72) 15 (22%) 38 (40) 2 (5%) 25 (27) 0
1997 155 (67) 14 (9%) 94 (41) 0 74 (32) 2 (3%)
1998 342 (64) 24 (7%) 183 (34) 0 140 (26) 0
1999 824 (70) 52 (6%) 411 (35) 7 (2%) 365 (31) 2 (0.5%)
2000 817 (69) 43 (5%) 439 (37) 9(2%) 316 (27) 2 (1%)
2001§ 527 (63) 13 (3%) 171 (20) 1 (0.6%) 121 (14) 0
Cases on LCC
1994 330 (66) 45 (14%) 154 (31) 19 (12%) 86 (18) 5 (6%)
1995 508 (65) 75 (15%) 354 (45) 15 (4%) 179 (23) 4 (2%)
1996 564 (60) 59 (11%) 385 (41) 7 (2%) 223 (24) 4 (2%)
1997 302 (49) 15 (5%) 188 (31) 5 (3%) 86 (14) 3 (4%)
1998 263 (40) 19 (7%) 127 (19) 7 (6%) 80 (12) 2 (3%)
1999 182 (57) 7 (4%) 86 (27) 1 (1%) 68 (21) 2 (3%)
2000 46 (68) 1 (2%) 9 (13) 0 4 (6) 0
2001§ 2 (29) 1 2 (29) 0 1 (14) 0
Unknown regimen
1994 0 0 2 (29) 1 2 (29) 0
1995 9 (7) 0 4 (3) 0 3 (2) 0
1996 25 (19) 0 9 (7) 0 3 (2) 0
1997 23 (22) 0 11 (11) 0 3 (3) 0
1998 27 (34) 0 19 (24) 0 5 (6) 0
1999 4 (21) 0 1 (5) 0 1 (5) 0
2000 4 (33) 0 1 (8) 0 0 0
2001§ 5 (36) 0 17) 0 2 (14) 0
sm+ = sputum smear positive for acid-fast bacilli out of examined.
SCC = short course chemotherapy; LCC = long course chemotherapy; AFB = acid-fast bacilli.
§Follow-up smears for the 5th month and end of treatment were not complete for the year 2001 as a considerable number of patients were still on 
treatment during the time of data collection.BMC Public Health 2005, 5:62 http://www.biomedcentral.com/1471-2458/5/62
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month and end of treatment smear-positivity (treatment
failure), than those on SCC (p < 0.05; table 4).
Treatment results
We analysed treatment outcomes for the years 1994–2000
and, as a result, we evaluated 16943 (85% of the total)
cases. Of these, 8268 (49%) successfully completed treat-
ment, 3151 (18.6%) defaulted, 110(0.6%) had treatment
failure, 446 (2.6%) died and 2000 (10%) were transferred
out, while 2968 (17.5%) had no record of treatment out-
comes. Assuming that patients with unrecorded treatment
outcome had all defaulted from treatment, a total of 6119
(36.1%) patients defaulted.
Among new PTB+ (and all TB) patients, treatment success
was higher among patients on SCC, while default and fail-
ure rates were higher among those on LCC (Table 5).
Death in all categories was higher among those on SCC.
Among new cases on SCC, PTB+ cases had 1.8 (65%
vs.37%) and 1.4 (65% vs. 48%) times higher rate of treat-
ment success compared to PTB- and EPTB cases, respec-
tively (p < 0.001). Female PTB+ patients had significantly
higher treatment success (58% vs. 54%; p = 0.001) and
lower defaulter rate (26% vs. 30%; p < 0.001) than males.
Patients registered as "return after default", had signifi-
cantly lower treatment success compared to new cases,
both for all TB (34% vs. 49%; p < 0.001), and for PTB+
(34% vs. 58%; p < 0.001). Furthermore, return after
default cases were more likely to default again compared
to new cases among PTB+ patients (53% vs. 29%; p <
0.001) and all TB patients (53% vs. 36%; p < 0.001).
Treatment failure was five times higher among cases that
received re-treatment for previous failure compared to
new cases of PTB+ (6.4% vs. 1.2%; p < 0.001); however,
both groups had comparable treatment success, mainly
due to a lower defaulter rate among failure cases (24% vs.
29%).
Patients for whom follow-up sputum smear remained
positive at the second month during treatment had signif-
icantly lower treatment success than those with negative
smear result (53% vs. 74%; p < 0.001), mainly as a result
of higher defaulter (24% vs. 18%) and failure (10% vs.
1%) rates among the former group.
Table 6 presents treatment outcomes for new cases of TB
across the years. A steady rise in treatment success and
decline in defaulter rate was noticed particularly among
patients on SCC. Treatment failure showed a remarkable
decline in both SCC and LCC groups. Death rate did not
show much variation across the years.
When we adjusted the outcome measures for treatment
results by various potentially confounding variables, sig-
nificantly higher treatment success was exhibited among
female patients, those 15–24 years, patients treated with
SCC, those on re-treatment for relapse, PTB+ cases, those
treated during 2000 and those treated in the Lemmo dis-
trict health facilities (Table 7). Meanwhile, male patients,
Table 5: Treatment outcomes for different categories of patients on short and long course regimens (n = 16943)
New cases
PTB+ (%) PTB- (%) EPTB (%) Relapse (%) After default (%) After failure (%) Transferred in (%)
Patients on SCC
Treatment success 2166 (65) 475 (37) 436 (48) 62 (66) 49 (46) 65 (53) 79 (64)
Default* 726 (22) 483 (37) 320 (36) 13 (14) 45 (42) 31 (25) 33 (26)
Failure 25 (0.7) - - 2 (2) 1 (1) 6 (5) 3 (2)
Death 117 (3.5) 72 (5) 24 (3) 11 (12) 5 (5) 2 (1) 2 (2)
Transferred out 306 (9) 269 (21) 118 (13) 6 (6) 7 (7) 18 (15) 7 (6)
Patients on LCC
Treatment success 1986 (51) 772 (39) 1932 (42) 14 (56) 32 (25) 11 (61) 189 (59)
Default* 1365 (35) 972 (48) 1922 (42) 8 (33) 79 (61) 2 (11) 24 (8)
Failure 66 (2) - - 1 (4) 2 (2) 3 (17) 1 (0.3)
Death 107 (3) 57 (3) 37 (1) 2 (8) 2 (2) 1 (5) 7 (2)
Transferred out 350 (9) 204 (10) 697 (15) - 14 (11) 1 (6) 3 (1)
* Patients with missing treatment outcome information were assumed to have defaulted and analysed as defaulters.
PTB+ = smear positive pulmonary tuberculosis; PTB- = smear negative pulmonary tuberculosis; EPTB = extra-pulmonary tuberculosis
SCC = short course chemotherapy (2 months on RHZ+/- E or S, followed by 6 months on EH or RH)
LCC = long course chemotherapy (2 months on EH +/-S, followed by 10 months on EH; TH had also been used as an alternative to EH until its 
recent withdrawal).
R = Rifampicin,; H = Isoniazid; Z = Pyrazinamide; E = Ethambutol; S = Streptomycin; T = Thioacetazone.BMC Public Health 2005, 5:62 http://www.biomedcentral.com/1471-2458/5/62
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patients aged 45–54, PTB- cases, those on LCC, return
after default cases and those treated in Duna district
health facilities exhibited significantly higher default rate.
Trend over time
DOTS was initiated in 1996 in a hospital and one health
centre, with potential population coverage of 25%
(defined as population living within 2 hours walking dis-
tance from a health facility; estimated at 250,000 for the
hospital and 25000 for the health centre). The number of
health facilities providing DOTS increased to 10 in 1997,
30 in 1999 and 41 in 2001, making the population cover-
age by DOTS 31%, 58% and 75% respectively. The pro-
portion of patients treated with SCC increased from 7% in
1994 to 27% in 1998, 58% in 1999, and 97% in 2001.
95% (39/41) of the treatment centres had at least isoni-
azid, rifampicin, pyrazinamide and ethambutol at the
time of visit for data collection. Reagents for Acid-fast
stain were available in nine of the 13 diagnostic centres
functioning at the time.
Table 6: Treatment outcomes across the years for new cases of tuberculosis
1994 n (%) 1995 n (%) 1996 n (%) 1997 n (%) 1998 n (%) 1999 n (%) 2000 n (%)
PTB+ on SCC
Treatment success 5 (42) 40 (34) 45 (38) 122 (47) 338 (60) 811 (69) 805 (74)
Default* 5 (42) 61 (51) 50 (42) 77 (30) 114 (20) 225 (19) 194 (17)
Failure - 3 (3) 2 (2) 2 (1) - 8 (1) 10 (1)
Death - 4 (3) 2 (2) 10 (4) 24 (4) 44 (4) 33 (3)
Transferred out 2 (17) 11 (9) 20 (17) 46 (18) 89 (16) 88 (7) 50 (5)
PTB+ on LCC
Treatment success 188 (38) 384 (48) 564 (56) 271 (45) 308 (52) 231 (72) 40 (68)
Default* 190 (38) 298 (38) 304 (30) 246 (40) 240 (40) 72 (22) 15 (25)
Failure 23 (5) 18 (2) 8 (1) 8 (1) 6 (1) 3 (1) -
Death 17 (3) 21 (3) 18 (2) 20 (3) 19 (3) 9 (3) 3 (5)
Transferred out 78 (16) 71 (9) 107 (11) 63 (10) 24 (4) 6 (2) 1 (2)
PTB- on SCC
Treatment success 1 (8) 15 (23) 18 (20) 32 (29) 67 (30) 153 (39) 189 (47)
Default* 8 (67) 40 (60) 67 (74) 55 (50) 85 (38) 116 (29) 112 (28)
Death 1 (8) 6 (9) 2 (2) 10 (9) 8 (4) 25 (6) 20 (5)
Transferred out 2 (17) 5 (8) 3 (3) 12 (11) 65 (29) 101 (26) 81 (20)
PTB- on LCC
Treatment success 107 (44) 88 (31) 84 (34) 78 (31) 199 (37) 182 (50) 34 (47)
Default* 101 (42) 163 (57) 127 (51) 141 (57) 280 (51) 135 (37) 25 (34)
Death 4 (2) 5 (2) 6 (2) 5 (2) 16 (3) 20 (6) 1 (1)
Transferred out 30 (12) 30 (11) 31 (13) 27 (11) 48 (9) 25 (7) 13 (18)
EPTB on SCC
Treatment success 4 (21) 19 (26) 25 (44) 29 (32) 43 (44) 101 (51) 215 (56)
Default* 11 (58) 43 (59) 29 (51) 30 (33) 29 (30) 68 (35) 110 (28)
Death 2 (11) 6 (8) 1 (2) 3 (4) 1 (1) 4 (2) 7 (2)
Transferred out 2 (11) 5 (7) 2 (4) 28(31) 24 (25) 24 (12) 53 (14)
EPTB on LCC
Treatment success 80 (35) 274 (49) 559 (52) 387 (36) 341 (34) 222 (43) 69 (50)
Default* 122 (52) 203 (36) 321 (30) 412 (39) 553 (56) 253 (49) 58 (42)
D e a t h 2  ( 1 )3  ( 1 ) 3  ( 0 . 3 )7  ( 1 )8  ( 1 ) 1 4  ( 3 ) -
Transferred out 28 (12) 85 (15) 198 (18) 260 (24) 91 (9) 24 (5) 11 (8)
* Patients with missing information on treatment outcome were assumed to have defaulted and analysed as defaulters.
PTB+ = smear positive pulmonary tuberculosis; PTB- = smear negative pulmonary tuberculosis; EPTB = extra-pulmonary tuberculosis
SCC = short course chemotherapy (2 months on RHZ+/- E or S, followed by 6 months on EH or RH)
LCC = long course chemotherapy (2 months on EH +/-S, followed by 10 months on EH; TH had also been used as an alternative to EH until its 
recent withdrawal).
R = Rifampicin,; H = Isoniazid; Z = Pyrazinamide; E = Ethambutol; S = Streptomycin; T = Thioacetazone.BMC Public Health 2005, 5:62 http://www.biomedcentral.com/1471-2458/5/62
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Simultaneously, treatment success for new PTB+ patients
(on SCC and LCC together) increased from 38% in 1994
to 56% in 1998, 70% in 1999 and 73% in 2000 (χ 2
trend, p
< 0.001). Defaulting among new PTB+ patients declined
from 38% in 1994 to 30% in 1998, 20% in 1999 and 18%
in 2000 (χ 2
trend, p < 0.001). Treatment failure decreased
from 5% in 1994 to 1% in 2000. The proportion of
reported deaths remained unchanged over years with
some variations in the range of 2–5%.
Treatment at small and large centres
Thirty-one out of 40 (77.5%) peripheral treatment centres
had significantly higher treatment success, and 28 (70%)
of them had significantly lower defaulter rate compared to
Table 7: Adjusted odds ratios for various factors that might affect treatment outcomes among registered tuberculosis patients
Treatment success (all TB) Default (all TB)
Characteristic Percent1 Adjusted OR* (95% CI) p-value Percent1 Adjusted OR* (95% CI) p-value
Sex
Male 45.5 1.00 37.5 1.00
Female 49.4 1.15(1.08–1.23) <0.001 34.0 0.88(0.82–0.94) <0.001
Age group (years)
0–14 42.6 0.83 (0.75–0.92) <0.001 41.2 1.17 (1.06–1.30) 0.002
15–24 (reference group) 51.1 1.00 33.4 1.00
25–34 47.5 0.84(0.77–0.91) <0.001 34.4 1.07 (0.98–1.17) 0.14
35–44 45.7 0.76 (0.68–0.84) <0.001 36.1 1.14 (1.03–1.28) 0.02
45–54 44.9 0.69 (0.60–0.79) <0.001 37.7 1.26 (1.09–1.46) 0.002
55–64 51.4 1.04 (0.84–1.29) 0.71 35.4 1.04 (0.81–1.27) 0.90
≥  65 37.4 0.67 (0.48–0.93) 0.02 43.7 1.27 (0.92–1.726 0.15
Patient category
New 47.0 1.00 35.9 1.00
Transferred-in 59.5 1.09 (0.89–1.36) 0.40 35.7 1.19 (0.95–1.48) 0.13
Return after default 33.9 0.68 (0.51–0.92) 0.01 52.9 1.57 (1.19–2.07) 0.002
Treatment failure 54.3 1.30 (0.91–1.86) 0.15 23.6 0.72 (0.48–1.09) 0.12
Relapse 62.9 1.51(1.01–2.26) 0.05 16.9 0.50 (0.30–0.82) 0.006
TB type
Pulmonary positive 55.3 1.00 28.7 1.00
Pulmonary negative 37.5 0.55 (0.50–0.60) <0.001 43.7 2.06 (1.87–2.26) <0.001
Extra-pulmonary 42.4 0.51 (0.47–0.55) <0.001 41.1 1.94 (1.78–2.11) <0.001
Treatment regimen
Short course chemotherapy 55.5 1.00 27.7 1.00
Long course chemotherapy 45.0 0.68 (0.62–0.75) <0.001 40.9 1.46 (1.33–1.61) <0.001
Treatment Centre**
Hossana Hospital 27.0 1.00 40.0 1.00
Lemmo district HF 60.4 5.14 (4.62–5.72) <0.001 20.6 0.28 (0.25–0.31) <0.001
Shashogo district HF 50.8 2.81 (2.41–3.28) <0.001 44.1 1.18 (1.01–1.37) 0.04
Misha district HF 60.3 4.78 (4.23–5.39) <0.001 33.0 0.58 (0.51–0.65) <0.001
Gibe district HF 60.7 4.78 (4.20–5.45) <0.001 26.2 0.51 (0.45–0.59) <0.001
Soro district HF 50.5 2.70 (2.39–3.06) <0.001 42.5 1.11 (0.98–1.26) 0.09
Duna district HF 30.2 0.77 (0.55–1.08) 0.12 67.3 5.18 (3.71–7.24) <0.001
Badewacho district HF 41.1 1.64 (1.44–1.86) <0.001 54.4 2.11 (1.86–2.40) <0.001
Year of treatment
1994 38.4 1.00 42.7 1.00
1995 40.6 1.18 (0.99–1.39) 0.06 39.9 1.17 (1.00–1.37) 0.05
1996 48.7 1.29 (1.10–1.51) 0.002 33.3 0.83 (0.71–0.97) 0.02
1997 38.9 0.72 (0.61–0.85) <0.001 39.5 1.08 (0.93–1.27) 0.32
1998 41.9 0.74 (0.63–0.87) <0.001 43.8 1.20 (1.03–1.40) 0.02
1999 56.7 1.37 (1.16–1.62) <0.001 30.0 0.59 (0.5–0.70) <0.001
2000 59.8 1.41 (1.18–1.69) <0.001 25.8 0.54 (0.45–0.65) <0.001
OR = odds ratio; CI = confidence intervals; HF = Health facilities
* All the variables in the table are included in the model.
** All treatment centres in a district grouped together as a unit.
1 Percentage out of total registered for treatment. Patients with missing outcome record were assumed to have defaulted and analysed as 
defaulters.BMC Public Health 2005, 5:62 http://www.biomedcentral.com/1471-2458/5/62
Page 9 of 11
(page number not for citation purposes)
the zonal hospital (details not shown). Further compari-
son by districts revealed that six of the seven rural districts
had significantly better treatment success while three out
of seven had lower defaulter rate than the zonal hospital
(Table 7).
Discussion
The results of our study show that there has been a contin-
uous increase in treatment success and eventual decline in
defaulter and failure rates in parallel to the expansion and
decentralisation of DOTS to the lower treatment units.
Treatment with SCC increased from a very low coverage in
1994 to almost full coverage in 2001 partly due to the
expansion of DOTS (with SCC as one of its elements), and
partly due to the regional TLCP commitment to SCC both
in DOTS and non-DOTS areas. However, trends in case
detection and notification showed inconsistencies over
years.
In the hierarchy of study designs, observational studies
come after the randomised controlled trials [17]. Never-
theless, in the real field condition, where randomised tri-
als are not logistically feasible, such observational study
designs may provide important and valid information.
Our study design does not allow comparison of treatment
outcomes between the DOTS and non-DOTS areas. How-
ever, this study gives us a valuable information on the pro-
gram performance before and along the course of
expanding DOTS in this resource-constrained rural
setting.
Four years after the introduction of DOTS in the zone, it
has been possible to achieve treatment success of 73% in
2000 for new PTB+ patients. Faring well towards the
WHO/IUATLD recommended 85%, this confirms the
finding of other studies [7,18] that the DOTS strategy
works well in resource-constrained settings with low over-
all health coverage. Increased coverage by SCC, improved
access to care through decentralisation of the service and
improved patient follow-up with the introduction of
DOTS have most likely played a significant role in
improving the treatment outcomes.
Higher treatment success and lower default among female
patients confirms previous study findings [11]. However,
the proportion of females among patients registered for
TB treatment was found to be consistently low, and it was
exceptionally lower among patients older than 45 years.
This may reflect a genuine gender difference in the TB epi-
demiology [19-21]. However, the possibility of this being
a reflection of gender differentials in access to health care
within the society may need to be ruled out by further
studies.
Patients treated at the peripheral treatment centres exhib-
ited better treatment outcomes compared to those treated
in the zonal hospital, which implies better follow-up of
cases or better access to the TB care services.
Despite significant decline in defaulter rate over time,
patients that received re-treatment as "return after
default", were much more likely to default again com-
pared to new patients. This group of defaulters seems
refractory to the conventional approach of treatment
supervision; social and cultural factors that might play a
role need to be explored. More death among patients on
SCC was an indication of the policy that severely sick
patients and those co-infected with HIV be a priority for
treatment by SCC and these groups were more likely than
others to die. Though lower among patients on SCC, the
high proportion of failure among patients retreated for
previous failure might signal the emergence of multi-drug
resistant TB (MDR-TB). Earlier studies have shown that
MDR has so far been below 1% [22,23].
The proportion of PTB+ was fairly stable in the range of
40–50% across the years, which indicates that the diag-
nosticians uniformly observed the diagnostic algorithms
recommended by the NTLCP. The case detection rate
(CDR), as estimated by the proportion of expected inci-
dent cases notified, showed an encouraging increase from
45% in 1994 to 115% in 1999, well above the CDR rec-
ommended by the WHO. The most plausible explanation
for this might be that the vigorous implementation of the
program during the earlier years of introduction of DOTS
might have enabled detection of a big pool of prevalent
cases of TB. But the pace in case detection could not be
maintained during 2000 and 2001 when the CDR fell to
94% and 67% respectively. Reduction in the incidence of
TB could be a possible explanation, but one cannot justify
such a fast decline in a very short time. This calls for some
case detection improvement initiatives to be in place as
the proportion of TB cases detected and cured under
DOTS is one of the health-related indicators of the millen-
nium development goals [24]. Quality of the laboratory
services and the possibility of under-reporting are among
factors to be explored further.
Two major areas of program weakness need to be
addressed. First, 94% of the patients were registered as
new cases, which suggests that some re-treatment cases
had been wrongly classified as new. Further, treatment
outcomes have not been recorded for about one-fifth of
the patients. Improving the record keeping system seems
to be an immediate priority. Second, the proportion of
PTB+ patients who had follow-up sputa examined for AFB
was low. The threat of anti-TB drug resistance is immi-
nent, and it is important to strengthen patient follow-up
with sputum examinations. About one-third of theBMC Public Health 2005, 5:62 http://www.biomedcentral.com/1471-2458/5/62
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peripheral diagnostic facilities lacked reagents for Ziehl-
Neelsen stain during the time of visit, and this might
partly explain the low performance.
Conclusion
The introduction and expansion of DOTS in Hadiya has
led to a significant increase in treatment success and
decrease in default and failure rates. The smaller institu-
tions exhibited better treatment outcomes compared to
the larger ones including the zonal hospital. The high
number of patients with missing information in the unit
registers is perhaps an issue that needs to be addressed as
urgently as possible. Further studies are recommended to
see the impact of the programme on the prevalence and
incidence of tuberculosis.
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